Sep 29, 2016 by Brian FeroldiWhy Intra-Cellular Therapies Inc. Is Crashing TodayShares plunge in the wake of disappointing clinical results from an important phase 3 trial.
Sep 29, 2016 by Brian Feroldi3 Top Stocks Under $10Low priced stocks with good growth prospects aren't easy to find, but they do exist.
Sep 28, 2016 by Brian FeroldiBetter Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics IncThese two biotechs have headed in opposite directions this year. Which one is the better choice for new money today?
Sep 28, 2016 by Brian Feroldi, Cory Renauer, and Todd Campbell3 Stocks to Avoid in HealthcareOur team of healthcare contributors thinks you should steer clear of these three companies.
Sep 27, 2016 by Brian FeroldiHere's Why Ligand Pharmaceuticals Inc Is Plunging TodayShares drop in response to its partner Amgen reporting less-than-stellar clinical data.
Sep 27, 2016 by Brian Feroldi, Keith Speights, and Cheryl SwansonThe 3 Best-Run Companies in the Healthcare SectorGreat management teams lead to great results, and our contributors believ these three companies have the best leaders in the business.
Sep 26, 2016 by Brian Feroldi3 Growth Stocks You Can Buy Cheap Right NowWall Street has punished these companies recently, but that just means it's a great time to buy them at a discount.
Sep 26, 2016 by Brian FeroldiHere's Why DURECT Corporation Is Tanking TodayNews that the FDA has rejected its partner's NDA submission has investors heading for the exits.
Sep 26, 2016 by Brian FeroldiWhy Array BioPharma Inc Is Surging TodayShares jump in response to the company posting good-looking clinical data from an important phase 3 trial.
Sep 26, 2016 by Brian Feroldi3 Stocks That Have Been Cut in Half This QuarterIt's been a brutal 90 days for investors in these companies.
Sep 26, 2016 by Brian Feroldi, Sean Williams, and Matt DiLallo3 Stocks Wall Street Unjustly HatesOut team of contributors thinks the markets are unfairly punishing these three companies right now, which could make it a great time to get in.
Sep 25, 2016 by Brian Feroldi, Cory Renauer, and George Budwell, PhD3 Bold Bets on the Future of BiotechnologyThese three companies have wagered millions on moonshot concepts.
Sep 23, 2016 by Brian Feroldi2 Stocks I'd Never Buy, and 1 I'll ConsiderI'm wary about investing in all three of these companies, but I'd only consider changing my tune on one of them.
Sep 23, 2016 by Brian FeroldiHere's How to Find the Best Dividend StocksPicking the right income stocks isn't easy, but this simple checklist can stop you from buying the wrong ones.
Sep 22, 2016 by Brian FeroldiHate Risk? You'll Love These 3 StocksThese three stocks are about as safe as it gets.
Sep 20, 2016 by Brian FeroldiWhy Amphastar Pharmaceuticals, Inc. is Soaring TodayTraders bid up shares on the news that the company's stock will be added to an index.
Sep 20, 2016 by Brian FeroldiHere's Why Sarepta Therapeutics, Inc's Stock is Jumping AgainShares soar in response to a handful of analysts turning bullish.
Sep 20, 2016 by Brian FeroldiDoes Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?Shares nearly doubled in response to the thumbs up from U.S. regulators on eteplirsen, its treatment for Duchenne muscular dystrophy. Should investors hop on board now?
Sep 18, 2016 by Brian Feroldi3 Stocks I'm Never SellingThese three companies are built to last, so I plan on hanging on to them for the ultra-long term.
Sep 17, 2016 by Brian FeroldiHere's My Top Stock to Buy in SeptemberThe combination of strong growth prospects and an attractive valuation make this my top stock to buy right now.
